BOSTON–(BUSINESS WIRE)–Corsera Health, Inc., a clinical-stage company leading the future of cardiovascular health through prediction and prevention, announced today that it has initiated a Phase 1 trial of COR-1004 and COR-2003 in Australia and New Zealand. The trial will evaluate COR-2003 alone as well as the co-administration of COR-1004 and COR-2003, marking the first clinical evaluation of this dual-targeting approach for the prevention of cardiovascular disease. COR-1004 is a novel inves

Subscribe to Our Newsletter

We keep your data private and share your data only with third parties that make this service possible. See our Privacy Policy for more information.